

Nonpesticide Agent Suffocates Head Lice Safely

BY SHERRY BOSCHERT
San Francisco Bureau

SAN FRANCISCO — Suffocating head lice with a benzyl alcohol product appears to be a safe and effective alternative to current therapies, industry-sponsored studies suggest.

Unlike many other lice therapies, the “lice asphyxiator” product does not contain pesticides. Therefore it shouldn’t carry the potential for the lice to develop re-

sistance, Terri Meinking wrote in a poster presentation at the annual meeting of the American Academy of Dermatology.

The increasing incidence of head lice in the past 8 years has been largely a result of lice becoming more tolerant or resistant to conventional treatments. “For this reason, children are being overtreated with pesticide-containing products as well as unconventional treatments,” noted Ms. Meinking of Global Health Associates of Miami Inc. and her associates. Global Health Associ-

ates is a contract research organization.

The active ingredient in Summers Non-pesticide Lice Asphyxiator, benzyl alcohol, works by stunning the louse’s respiratory spiracles open, thereby allowing the product to mechanically block the respiratory system. Ms. Meinking, also of the department of dermatology and cutaneous surgery at the University of Miami, and her associates tested the safety and efficacy of this product in three randomized, observer-blinded studies sponsored by

Summers Laboratories Inc., which makes the product.

Patients came from an area of high lice infestation in South Florida and had a high probability of being reinfested after treatment. They ranged in age from 2 to 70 years and had at least 3 live head lice and 10 eggs at study entry.

In the first study, 81 patients enrolled and 79 completed the study, which involved two applications for 10 minutes, 1 week apart, of a 5% or 10% concentration of the asphyxiator product, vehicle alone, or RID shampoo. Patients who were treated with the asphyxiator or RID who still had live lice 1 week after the initial treatment (day 8), were re-treated with the same product. Those who initially had been given placebo and had live lice on day 8 were treated with the 5% asphyxiator.

At day 1 after the first treatment, the kill rate was more than 80% among the 20 patients who had applied a 5% solution of the asphyxiator and among the 20 patients who had applied a 10% solution of the product. This was the same kill rate seen

The increasing incidence of head lice in the past 8 years has been largely a result of lice becoming more tolerant or resistant to conventional treatments.

among the 20 patients who had applied RID shampoo, a pyrethrin-piperonyl-butoxide pediculicide. In comparison, the kill rate was less than 20% among the 19 patients who applied vehicle alone (placebo).

At day 15, all three active treatment groups had achieved a 70% success rate in eradicating live lice. The success rate was 53% among those in the placebo group. Only one adverse event, a mild burning on the scalp experienced by a patient in the RID group, was thought to possibly be treatment related.

Investigators noted that some of the scalps probably were insufficiently saturated to fully suffocate the lice and hypothesized that this may have been why success rates in the treatment groups were not higher.

In the second study, Ms. Meinking and her associates corrected for this and looked at duration of application. They compared 10- and 30-minute applications of the 5% concentration of the asphyxiator product on fully saturated hair in 44 patients, 43 of whom completed two applications, 1 week apart, and returned for follow-up on day 15. At follow-up, the success rate was 100% for all 21 patients randomized to apply the solution for 10 minutes and for all 22 who had applied it for 30 minutes. No treatment-related adverse events were noted.

The investigators then evaluated whether a 5% concentration of the asphyxiator was more effective than a 2.5% solution. At day 15, the overall treatment success was 91% among the 18 patients given the higher dose and 81% of the 21 given the lower dose. The 5% concentration is the dose of choice, they concluded. ■


Brought to you by **sanofi aventis**

THE ECS IMPACTS THE METABOLISM OF LIPIDS AND GLUCOSE¹⁻³

- ECS overactivity may be associated with the development of cardiometabolic risk factors including:
 - Low HDL cholesterol
 - High triglycerides
 - High waist circumference
 - Elevated fasting glucose
 - Insulin resistance

THE ECS HELPS REGULATE PHYSIOLOGIC PROCESSES¹⁻⁴

- The ECS consists of signaling molecules and their receptors, including the cannabinoid receptor CB₁²
- Endocannabinoids bind to CB₁ receptors and trigger events that may have a negative impact on lipid levels and insulin sensitivity¹
- CB₁ receptors are located in sites such as muscle, the liver, the brain, and adipose tissue^{1,2,4,6}



RESEARCH CONTINUES TO INVESTIGATE THE ROLE OF CB₁ RECEPTORS IN MUSCLE*

- Reduced glucose uptake has been observed in isolated skeletal muscle of genetically obese, insulin-resistant animals



ENDOCANNABINOID TARGET FATTY ACID PRODUCTION IN THE LIVER³

- May contribute to dyslipidemia and insulin resistance^{3,7}



PRESENT IN MULTIPLE AREAS OF THE BRAIN²

- Hypothalamus integrates signals from adipose tissue and other peripheral tissues^{8,9}



ADIPOSE TISSUE—MORE THAN SIMPLY A FAT STORAGE DEPOT

- Produces factors active in the metabolism of lipids and glucose¹⁰
- Low levels of adiponectin negatively affect glucose and free fatty acids^{1,10}

EXPLORING THE EFFECTS OF THE ECS

- This newly discovered physiologic system provides new opportunities for understanding cardiometabolic risk

*Data from animal model only.

References

1. Bensaid M, Gary-Bobo M, Esclançon A, et al. The cannabinoid CB₁ receptor antagonist SR141716 increases Acip30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. *Mol Pharmacol*. 2003;63:908-914.
2. Harrold JA, Williams G. The cannabinoid system: a role in both the homeostatic and hedonic control of eating? *Br J Nutr*. 2003;90:729-734.
3. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB₁ receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. *J Clin Invest*. 2005;115:1298-1305.
4. Domenicali M, Ros J, Fernández-Varo G, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. *Gut*. 2005;54:522-527.
5. Rhee M-H, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. *J Neurochem*. 1998;71:1525-1534.
6. Upham BL, Rummel AM, Carbone JM, et al. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. *Int J Cancer*. 2003;104:12-18.
7. Flier JS, Maratos-Flier E. Obesity. In: Kasper DL, Braunwald E, Fauci AS, et al, eds. *Harrison's Principles of Internal Medicine*. 16th ed. New York, NY: McGraw-Hill; 2005:chap 64. Available at: <http://www.accessmedicine.com/content.aspx?alD=60099&searchStr=obesity>. Accessed December 5, 2005.
8. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. *Science*. 2005;307:1909-1914.
9. Devaskar SU. Neurohumoral regulation of body weight gain. *Pediatr Diabetes*. 2001;2:131-144.
10. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab*. 2004;89:2548-2556.